Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • IMI

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

    More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

    - PMLiVE

    J&J receives three CHMP recommendations for immunology and oncology indications

    Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

    - PMLiVE

    J&J submits EU and US applications for subcutaneous Darzalex in smouldering multiple myeloma

    The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

    - PMLiVE

    J&J’s Darzalex regimen approved by EC for newly diagnosed multiple myeloma

    More than 35,000 cases of the incurable blood cancer were diagnosed in the EU in 2022

    - PMLiVE

    Levicept’s NT-3 inhibitor shows promise in moderate-to-severe osteoarthritis

    The degenerative joint disease affects more than 32.5 million adults in the US

    - PMLiVE

    J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

    Darzalex treatment regimen reduced risk of death by 32% after nearly five years follow-up

    - PMLiVE

    Janssen scores another expansion for new Darzalex combination in the US

    Myeloma med approved in combination with Amgen's Kyprolis

    Sanofi reception

    FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

    First cancer drug wholly owned by company to be approved in past decade

    - PMLiVE

    Janssen files new Darzalex combination for multiple myeloma

    Expands use of anti-CD38 antibody even further

    - PMLiVE

    J&J wins another label expansion for Darzalex in Europe

    Multiple myeloma treatment indicated for early use

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links